Peter S. Nelson, MD (Clinical Investigator Mentor, Damon Runyon Scholar ‘02-‘04) of Fred Hutchinson Cancer Research Center, Seattle, and colleagues, conducted the first comprehensive assessment of the genome of advanced, lethal prostate cancer. They discovered a number of recurrent genetic mutations common to advanced prostate cancer that may contribute to disease progression and resistance to commonly used therapies. The researchers hope that these findings will lead to development of new strategies for diagnosis and treatment. The study was published in the Proceedings of the National Academy of Sciences.